¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷) : 2023-02-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷) : 2023-02-26
±³À°ÀÏÀÚ : 2023-02-26
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ  
±³À°ÁÖÁ¦ : Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : ½ÅÀåÇÐȸ»ç¹«±¹
¿¬¶ôó : 02-3486-8736  
À̸ÞÀÏ : ksn@ksn.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 160,000¿ø      
ºñ°í BRC (ÀüÀÏ) + ARC (3/26):160,000 ¿ø, BRC (1ÀÏ) + ARC (3/26) 120,000 ¿ø BRC (1ÀÏ): 80,000 ¿ø, ¸¸65¼¼ ÀÌ»ó ȸ¿ø, Çлý:¸éÁ¦      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 09:00~09:30 Basic renal pathology and evaluation of primary glomerular disease   ±Ç±â¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 09:30~10:00 An update on the management of IgA nephropathy   °­¼®ÈÖ(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 10:00~10:30 Immunoglobulin- and complement-mediated glomerular diseases with an MPGN pattern of injury  ¹Ú¼±Èñ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 10:30~11:00 Overview of the pathogenesis and treatment of ANCA-associated GN (ARC ¿¬°è °­ÀÇ)  È«À¯¾Æ(°¡Å縯ÀÇ´ë) 
È޽Ġ02-26  11:00~11:10 Break  () 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 11:10~11:40 How to use SGLT2 inhibitor and GLP-1 receptor agonist in diabetic kidney disease (ARC ¿¬°è °­ÀÇ)  ±æÈ¿¿í(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 11:40~12:10 Pathophysiology of diabetic kidney disease  ¹®ÁÖ¿µ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 12:10~12:40 Optimal treatment of dyslipidemia in diabetic kidney disease   À¯ÅÂÇö(¿¬¼¼ÀÇ´ë) 
½Ä»ç 02-26  12:40~13:30 Lunch Break  () 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 13:30~14:00 Evaluation for resistant hypertension in advanced CKD patients  ÀÌÁ¤È¯(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 14:00~14:30 Treatment of osteoporosis in CKD  ±èÁ°æ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 14:30~15:00 Optimal management of anemia: EPO, iron, and new therapeutics  °í°­Áö(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 15:00~15:30 Hypertension management in kidney transplant recipients  Á¤Á¾Ã¶(¼­¿ïÀÇ´ë) 
È޽Ġ02-26  15:30~15:40 Break  () 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 15:40~16:10 HDF vs. expanded hemodialysis (ARC ¿¬°è °­ÀÇ)  ÀÌ¿µ±â(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 16:10~16:40 Flow related complication of arteriovenous fistula (ARC ¿¬°è °­ÀÇ)  ¹ÚÈƼ®(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 16:40~17:10 How should we change the PD prescription when adequacy targets are not met?  ±Ç¼ø±æ(ÃæºÏÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷) : 2023-02-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ºû°íÀ»Àü³²´ëÇб³º´¿ø ·ù¸¶Æ¼½º³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2023-02-26
´ÙÀ½±Û ´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (1ÀÏÂ÷) : 2023-02-25
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
17 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø ôÃߺ´¿ø 8¿ù ¿ù·ÊÁý´ãȸ : 2018-08-02 0 370 2018-07-28
16 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-08-01 0 375 2018-07-28
15 ¼­¿ï 2018³âµµ ´ëÇÑÅëÁõÇÐȸ Á¦3Â÷ CADAVER WORKSHOP : 2018-07-29 0 729 2018-07-28
14 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø ¿µ»óȹµæÀÇ ±â¼úÀû Ãø¸é°ú Æó¾Ï °ËÁø : 2018-07-29 0 744 2018-07-28
13 ¼­¿ï ´ëÇѺÎÀÎÁ¾¾çÇÐȸ KGOG 2018 Summer Workshop Uterine Cancer : 2018-07-29 0 902 2018-07-28
12 ¼­¿ï ´ëÇÑ¿µ»óÀÇÇÐȸ »ó±ÙÀÇ»ç À¯¹æÃÔ¿µ¿ëÀåÄ¡ Ç°Áú°ü¸® ±³À° 3ÀÏÂ÷(7¿ù29ÀÏ) : 2018-07-29 0 834 2018-07-28
11 ¼­¿ï ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ 2018³âµµ ¡ººÐ¼®½É¸®ÇÐ ±âÃÊ°­Á¡»: 2018-07-29 0 853 2018-07-28
10 ¼­¿ï °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ 18 ȸ ü°èÀû ¹®Çå °íÂû[¸ÞŸºÐ¼®]À» ÅëÇÑ ³í¹®Ãâ°£ ¿öÅ©¼¥ : 2018-07-28 0 1,186 2018-07-28
9 °æ±â ¸íÁöº´¿ø ¿äÃò ¹× ½½°üÀý ÅëÁõ Ä¡·áÀÇ ÃÖ½ÅÁö°ß : 2018-07-28 0 1,150 2018-07-28
8 ¼­¿ï 2018³âµµ ´ëÇÑÅëÁõÇÐȸ Á¦3Â÷ CADAVER WORKSHOP : 2018-07-28 0 1,111 2018-07-28
7 ¼­¿ï ´ëÇÑÁ¾¾ç¿Ü°úÇÐȸ 2018³â ´ëÇÑÁ¾¾ç¿Ü°úÇÐȸ ¿¬¼ö°­Á : 2018-07-28 0 1,027 2018-07-28
6 °æ±â ´ëÇѳ»½Ã°æº¹°­°æ¿Ü°úÇÐȸ 2018 Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC) Symposium : 2018-07-28 0 1,272 2018-07-28
5 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø Hyperhidrosis Symposium : 2018-07-28 0 1,557 2018-07-28
4 ¼­¿ï °¡Å縯´ëÇб³¿©Àǵµ¼º¸ðº´¿ø 2018 The 11th Catholic Neurosurgery Update Symposium : 2018-07-28 0 1,436 2018-07-28
3 °æ±â ´ëÇÑ´ç´¢º´ÇÐȸ °æÀÎÁöȸEGDM (Essential Guideline to Diabetes Management) : 2018-07-28 0 2,241 2018-07-28
1411 | 1412 | 1413 | 1414 | 1415
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷